Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7061778 | 0.67 | SLC6A3 (0.43) | SLC6A3SLC6A2MAPTMEN1KMT2A | |
| SCHEMBL28240863 | 0.65 | MEN1 (0.53) | SLC6A3SLC6A2MAPTMEN1KMT2A | |
| SCHEMBL7464714 | 0.65 | SLC6A3 (0.59) | SLC6A3SLC6A2MAPTMEN1KMT2A | |
| SCHEMBL26967577 | 0.65 | KDM4E (0.41) | SLC6A3SLC6A2MAPTMEN1KMT2A | |
| SCHEMBL5240613 | 0.63 | SLC6A3 (0.58) | SLC6A3SLC6A2MAPTMEN1KMT2A | |
| SCHEMBL29137626 | 0.63 | SLC6A3 (0.38) | SLC6A3SLC6A2MAPTMEN1KMT2A | |
| SCHEMBL8752796 | 0.62 | MAPT (0.40) | SLC6A3SLC6A2MAPTMEN1KMT2A | |
| SCHEMBL577013 | 0.62 | SLC6A3 (0.43) | SLC6A3SLC6A2MAPTMEN1KMT2A | |
| SCHEMBL706765 | 0.62 | NR4A1 (0.42) | SLC6A3SLC6A2MAPTMEN1KMT2A | |
| SCHEMBL31616911 | 0.62 | MAPT (0.43) | MAPTMEN1KMT2AKDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124793-B2 | Derivatives of ethylene methanedisulfonate as cancer chemotherapeutic agents | CRONYN MARSHALL W (US) | 2012-02-28 | — | — | US | disclosed |
| US-20090176805-A1 | DERIVATIVES OF ETHYLENE METHANEDISULFONATE AS CANCER CHEMOTHERAPEUTIC AGENTS | CRONYN MARSHALL W | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176805-A1 | DERIVATIVES OF ETHYLENE METHANEDISULFONATE AS CANCER CHEMOTHERAPEUTIC AGENTS | MGMT, ETV6, EI24 | SLC6A3 3311/4885SLC6A2 4689/4885MAPT 4552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.